Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases
- Conditions
- Interventions
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2011-04-18
- Lead Sponsor
- Kanazawa University
- Target Recruit Count
- 20
- Registration Number
- NCT01337440
- Locations
- 🇯🇵
Internal medicine, Kanazawa university hospital, Kanazawa, Ishikawa, Japan
Metformin and Sitagliptin in Women With Previous Gestational Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 40
- Registration Number
- NCT01336322
- Locations
- 🇮🇹
Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Laval University
- Target Recruit Count
- 22
- Registration Number
- NCT01334229
- Locations
- 🇨🇦
Laval University, Quebec, Canada
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
- Conditions
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 653
- Registration Number
- NCT01296412
Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
- Conditions
- Interventions
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2014-03-14
- Target Recruit Count
- 16
- Registration Number
- NCT01272583
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Noord Holland, Netherlands
Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 12
- Registration Number
- NCT01260246
- Locations
- 🇨🇦
St. Joseph's Health Care, London, Ontario, Canada
Sitagliptin in Cystic Fibrosis-Related Diabetes
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 3
- Registration Number
- NCT01257464
- Locations
- 🇨🇦
University of British Columbia Gerontology & Diabetes Reserach Centre (ViTALITY), Vancouver, British Columbia, Canada
Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus
- First Posted Date
- 2010-11-08
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Command Hospital, India
- Target Recruit Count
- 20
- Registration Number
- NCT01235819
- Locations
- 🇮🇳
Command Hospital, Lucknow, UP, India
Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Sung-Chen Liu
- Target Recruit Count
- 120
- Registration Number
- NCT01195090
- Locations
- 🇨🇳
Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
Glycemic Holter Study (Continuous Glucose Monitoring) -
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 36
- Registration Number
- NCT01193296
- Locations
- 🇫🇷
Investigative Site, Venissieux, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.